243 related articles for article (PubMed ID: 19276275)
1. Randomized phase II designs.
Rubinstein L; Crowley J; Ivy P; Leblanc M; Sargent D
Clin Cancer Res; 2009 Mar; 15(6):1883-90. PubMed ID: 19276275
[TBL] [Abstract][Full Text] [Related]
2. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.
Tang H; Foster NR; Grothey A; Ansell SM; Goldberg RM; Sargent DJ
J Clin Oncol; 2010 Apr; 28(11):1936-41. PubMed ID: 20212253
[TBL] [Abstract][Full Text] [Related]
3. A Review of Perspectives on the Use of Randomization in Phase II Oncology Trials.
Grayling MJ; Dimairo M; Mander AP; Jaki TF
J Natl Cancer Inst; 2019 Dec; 111(12):1255-1262. PubMed ID: 31218346
[TBL] [Abstract][Full Text] [Related]
4. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
Pond GR; Abbasi S
Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
[TBL] [Abstract][Full Text] [Related]
5. Design issues of randomized phase II trials and a proposal for phase II screening trials.
Rubinstein LV; Korn EL; Freidlin B; Hunsberger S; Ivy SP; Smith MA
J Clin Oncol; 2005 Oct; 23(28):7199-206. PubMed ID: 16192604
[TBL] [Abstract][Full Text] [Related]
6. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
Taylor JM; Braun TM; Li Z
Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase II clinical trials.
Jung SH; Sargent DJ
J Biopharm Stat; 2014; 24(4):802-16. PubMed ID: 24697589
[TBL] [Abstract][Full Text] [Related]
8. Sample size computation in phase II designs combining the A'Hern design and the Sargent and Goldberg design.
Neven A; Mauer M; Hasan B; Sylvester R; Collette L
J Biopharm Stat; 2020 Mar; 30(2):305-321. PubMed ID: 31331234
[TBL] [Abstract][Full Text] [Related]
9. Optimising the design of phase II oncology trials: the importance of randomisation.
Ratain MJ; Sargent DJ
Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773
[TBL] [Abstract][Full Text] [Related]
10. Design issues in randomized phase II/III trials.
Korn EL; Freidlin B; Abrams JS; Halabi S
J Clin Oncol; 2012 Feb; 30(6):667-71. PubMed ID: 22271475
[TBL] [Abstract][Full Text] [Related]
11. Designs for randomized phase II clinical trials with two treatment arms.
Hou W; Chang MN; Jung SH; Li Y
Stat Med; 2013 Nov; 32(25):4367-79. PubMed ID: 23630064
[TBL] [Abstract][Full Text] [Related]
12. Integrated phase II/III clinical trials in oncology: a case study.
Wang M; Dignam JJ; Zhang QE; DeGroot JF; Mehta MP; Hunsberger S
Clin Trials; 2012 Dec; 9(6):741-7. PubMed ID: 23180870
[TBL] [Abstract][Full Text] [Related]
13. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
Jenkins M; Stone A; Jennison C
Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.
Korn EL; Liu PY; Lee SJ; Chapman JA; Niedzwiecki D; Suman VJ; Moon J; Sondak VK; Atkins MB; Eisenhauer EA; Parulekar W; Markovic SN; Saxman S; Kirkwood JM
J Clin Oncol; 2008 Feb; 26(4):527-34. PubMed ID: 18235113
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II trials: time for a new era in clinical trial design.
Mandrekar SJ; Sargent DJ
J Thorac Oncol; 2010 Jul; 5(7):932-4. PubMed ID: 20581575
[TBL] [Abstract][Full Text] [Related]
16. Phase II clinical trials in oncology: are we hitting the target?
Ang MK; Tan SB; Lim WT
Expert Rev Anticancer Ther; 2010 Mar; 10(3):427-38. PubMed ID: 20214523
[TBL] [Abstract][Full Text] [Related]
17. Designing phase II trials in cancer: a systematic review and guidance.
Brown SR; Gregory WM; Twelves CJ; Buyse M; Collinson F; Parmar M; Seymour MT; Brown JM
Br J Cancer; 2011 Jul; 105(2):194-9. PubMed ID: 21712822
[TBL] [Abstract][Full Text] [Related]
18. Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing.
Vickers AJ; Ballen V; Scher HI
Clin Cancer Res; 2007 Feb; 13(3):972-6. PubMed ID: 17277252
[TBL] [Abstract][Full Text] [Related]
19. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.
Gray R; Manola J; Saxman S; Wright J; Dutcher J; Atkins M; Carducci M; See W; Sweeney C; Liu G; Stein M; Dreicer R; Wilding G; DiPaola RS
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1966-9. PubMed ID: 16609005
[TBL] [Abstract][Full Text] [Related]
20. Improving the design of phase II trials of cytostatic anticancer agents.
Stone A; Wheeler C; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
